Education
About Us
Working with TipRanks
Follow Us
Corcept Therapeutics Inc. (CORT)
NASDAQ:CORT
CORT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$20.84 - $117.33
Previous CloseN/A
Volume78.39K
Average Volume (3M)1.95M
Market Cap
$7.85B
Enterprise Value$5.59B
Total Cash (Recent Filing)$18.55M
Total Debt (Recent Filing)$4.00K
Price to Earnings (P/E)60.4
Beta0.25
Next Earnings
Apr 30, 2025EPS Estimate
0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.23
Shares Outstanding105,503,430
10 Day Avg. Volume3,255,382
30 Day Avg. Volume1,949,171
Financial Highlights & Ratios
PEG Ratio1.88
Price to Book (P/B)N/A
Price to Sales (P/S)9.17
Price to Cash Flow (P/CF)26.10
P/FCF Ratio26.10
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.42
Enterprise Value/Ebitda40.67
Forecast
1Y Price Target
$137.60Price Target Upside84.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsRelacorilant achieves strong progression-free survival (PFS) and overall survival (OS) in ovarian cancer.
Financial PerformanceFY25 revenue guidance of $900-950M represents a 33.5% year-over-year growth.
Market PotentialRelacorilant could potentially receive a broader label than Elahere as it is not limited to FRα-positive patients.
Bears Say
CompetitionThe data presented showed similar overall survival outcomes between Elahere and relacorilant, suggesting competitive efficacy.
Past Financial AnomaliesKorlym's 4Q24 was an anomaly, focus on guidance.
Regulatory DependencyCorcept can file an NDA based on either PFS or OS results from the ROSELLA trial, providing flexibility in regulatory submissions.
---
Ownership Overview
15.17% Insiders
17.70% Mutual Funds
16.74% Other Institutional Investors
26.79% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CORT FAQ
What was Corcept Therapeutics Inc.’s price range in the past 12 months?
Corcept Therapeutics Inc. lowest stock price was $20.84 and its highest was $117.33 in the past 12 months.
What is Corcept Therapeutics Inc.’s market cap?
Corcept Therapeutics Inc.’s market cap is $7.85B.
When is Corcept Therapeutics Inc.’s upcoming earnings report date?
Corcept Therapeutics Inc.’s upcoming earnings report date is Apr 30, 2025 which is in 23 days.
How were Corcept Therapeutics Inc.’s earnings last quarter?
Corcept Therapeutics Inc. released its earnings results on Feb 26, 2025. The company reported $0.26 earnings per share for the quarter, missing the consensus estimate of $0.426 by -$0.166.
Is Corcept Therapeutics Inc. overvalued?
According to Wall Street analysts Corcept Therapeutics Inc.’s price is currently Undervalued.
Does Corcept Therapeutics Inc. pay dividends?
Corcept Therapeutics Inc. does not currently pay dividends.
What is Corcept Therapeutics Inc.’s EPS estimate?
Corcept Therapeutics Inc.’s EPS estimate is 0.14.
How many shares outstanding does Corcept Therapeutics Inc. have?
Corcept Therapeutics Inc. has 105,503,430 shares outstanding.
What happened to Corcept Therapeutics Inc.’s price movement after its last earnings report?
Corcept Therapeutics Inc. reported an EPS of $0.26 in its last earnings report, missing expectations of $0.426. Following the earnings report the stock price went down -5.555%.
Which hedge fund is a major shareholder of Corcept Therapeutics Inc.?
Currently, no hedge funds are holding shares in CORT
---
Corcept Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$137.60 (84.82% Upside)
$137.60 (84.82% Upside)
Blogger Sentiment
Bullish
CORT Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 22.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $226.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.1%
Last 30 Days ▲ 7.7%
Last 30 Days ▲ 7.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
197.20%
12-Months-Change
Fundamentals
Return on Equity
23.55%
Trailing 12-Months
Asset Growth
35.24%
Trailing 12-Months
Company Description
Corcept Therapeutics Inc.
Corcept Therapeutics (CORT) is a pharmaceutical company specializing in the development and commercialization of drugs that modulate the effects of cortisol. The company's primary focus is on developing treatments for severe metabolic, oncologic, and psychiatric disorders. Its flagship product, Korlym, is approved for the control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome.
---
CORT Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Corcept Therapeutics demonstrated strong financial performance with significant revenue and net income growth. The company made substantial progress in drug development, notably with relacorilant for hypercortisolism and potential cancer treatments. However, they faced operational challenges affecting revenue and a legal setback with Teva. Despite these issues, the overall outlook remains positive due to strategic advancements and strong financials.Read More>---
CORT Stock 12 Month Forecast
Average Price Target
$137.60
▲(84.82% Upside)
Technical Analysis
Amgen
―
Neurocrine
―
Vertex Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
SAGE Therapeutics
―
Best Analysts Covering CORT
1 Year
1 Year Success Rate
15/15 ratings generated profit
1 Year Average Return
+74.05%
reiterated a buy rating 7 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +74.05% per trade.
---